Roche's IMpassion130 Is First Positive Phase III Immunotherapy Study In Triple Negative Breast Cancer
Executive Summary
Phase III IMpassion130 study showed Tecentriq plus Abraxane significantly reduced the risk of disease worsening or death in people with metastatic triple negative breast cancer.